Država: Švedska
Jezik: švedščina
Source: Läkemedelsverket (Medical Products Agency)
flutikasonpropionat; formoterolfumaratdihydrat
Mundipharma AB
R03AK11
fluticasone propionate; formoterol
250 mikrogram/10 mikrogram/puff
Inhalationsspray, suspension
formoterolfumaratdihydrat 10 mikrog Aktiv substans; etanol, vattenfri Hjälpämne; flutikasonpropionat 250 mikrog Aktiv substans
Receptbelagt
Förpacknings: Inhalator, 120 puffar
Godkänd
2019-04-11
1 PACKAGE LEAFLET 2 PACKAGE LEAFLET: INFORMATION FOR THE USER ABRIFF 50 MICROGRAM /5 MICROGRAM PER ACTUATION PRESSURISED INHALATION, SUSPENSION ABRIFF 125 MICROGRAM /5 MICROGRAM PER ACTUATION PRESSURISED INHALATION, SUSPENSION ABRIFF 250 MICROGRAM /10 MICROGRAM PER ACTUATION PRESSURISED INHALATION, SUSPENSION fluticasone propionate/formoterol fumarate dihydrate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor <,or> pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor <,or> pharmacist Preberite celoten dokument. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET : 1. What ABRIFF is and what it is used for 2. What you need to know before you use ABRIFF 3. How to use ABRIFF 4. Possible side effects 5. How to store ABRIFF 6. Contents of the pack and other information 1. WHAT ABRIFF IS AND WHAT IT IS USED FOR Please note:- ABRIFF pressurised inhalation, suspension is the product name, however throughout this leaflet it is shortened to ABRIFF inhaler. Sometimes this may refer to a specific strength. ABRIFF is an inhaler (a pressurised inhalation suspension) which contains two active ingredients: Fluticasone propionate which belongs to a group of medicines called steroids. Steroids help to reduce swelling and inflammation in the lungs. Formoterol fumarate dihydrate which belongs to a group of medicines called long-acting beta 2 agonists. Long-acting beta 2 agonists are long-acting bronchodilators which help the airways in your lungs to stay open, making it easier for you to breathe. Together these two active ingredients help to improve your breathing. It is advised that you should use this medicine every day as directed
1 SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Abriff 50 microgram/5 microgram per actuation pressurised inhalation, suspension. Abriff 125 microgram/5 microgram per actuation pressurised inhalation, suspension. Abriff 250 microgram/10 microgram per actuation pressurised inhalation, suspension. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each metered dose (ex-valve) contains: 50 micrograms of fluticasone propionate and 5 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 46 microgram of fluticasone propionate/4.5 microgram of formoterol fumarate dihydrate. 125 micrograms of fluticasone propionate and 5 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 115 microgram of fluticasone propionate/4.5 microgram of formoterol fumarate dihydrate. 250 micrograms of fluticasone propionate and 10 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 230 microgram of fluticasone propionate/9.0 microgram of formoterol fumarate dihydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Pressurised inhalation, suspension The canister contains white to off white liquid suspension. The canister is in a white actuator with a grey integrated dose indicator and a light grey mouthpiece cover. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS This fixed-dose combination of fluticasone propionate and formoterol fumarate () is indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long -acting β 2 agonist) is appropriate: For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β 2 agonist. Or For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β 2 agonist. Preberite celoten dokument50 microgram _ /_ 5 microgram per